Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Ji-Guang | - |
dc.contributor.author | Kario, Kazuomi | - |
dc.contributor.author | Lau, Titus | - |
dc.contributor.author | Wei, Yong Quek | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Kim, Cheol Ho | - |
dc.contributor.author | Huang, Jun | - |
dc.contributor.author | Zhang, Weizhong | - |
dc.contributor.author | Li, Yong | - |
dc.contributor.author | Yan, Peter | - |
dc.contributor.author | Hu, Dayi | - |
dc.date.available | 2020-11-03T03:47:25Z | - |
dc.date.issued | 2011-04 | - |
dc.identifier.issn | 0916-9636 | - |
dc.identifier.issn | 1348-4214 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/13602 | - |
dc.description.abstract | Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease. Hypertension Research (2011) 34, 423-430; doi:10.1038/hr.2010.259; published online 13 January 2011 | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Japanese Society of Hypertension | - |
dc.title | Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1038/hr.2010.259 | - |
dc.identifier.scopusid | 2-s2.0-79953698165 | - |
dc.identifier.wosid | 000289194100003 | - |
dc.identifier.bibliographicCitation | Hypertension Research, v.34, no.4, pp 423 - 430 | - |
dc.citation.title | Hypertension Research | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 423 | - |
dc.citation.endPage | 430 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | CONVERTING ENZYME-INHIBITOR | - |
dc.subject.keywordPlus | ISOLATED SYSTOLIC HYPERTENSION | - |
dc.subject.keywordPlus | ANGIOTENSIN RECEPTOR BLOCKERS | - |
dc.subject.keywordPlus | AMBULATORY BLOOD-PRESSURE | - |
dc.subject.keywordPlus | LIPID-LOWERING TREATMENT | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | NIFEDIPINE-RETARD | - |
dc.subject.keywordPlus | CHINESE PATIENTS | - |
dc.subject.keywordAuthor | ambulatory blood pressure | - |
dc.subject.keywordAuthor | calcium channel blockers | - |
dc.subject.keywordAuthor | cardiovascular endpoints | - |
dc.subject.keywordAuthor | randomized controlled trials | - |
dc.subject.keywordAuthor | target organ damage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.